Peptide Schedule
PE-22-287 residuesGVSWGLREach bubble = one amino acid. Size = residue mass. Color = chemical class.

PE-22-28 Dosage Calculator

CognitiveInjection/NasalResearch~23 hours half-life

PE-22-28 is a synthetic heptapeptide (7 amino acids) derived from spadin, a naturally occurring fragment of the sortilin propeptide.

Rapid antidepressant-like effects in animal models (within 4 days)Stimulates hippocampal neurogenesis and BDNF expressionPotent TREK-1 channel blockade (IC50 0.12 nM)Extended duration of action (~23 hours vs. 7 hours for spadin)4 weeks on / 4 weeks off

100mcg · Daily

100500
4.0 units
100 units (1mL)
Concentration
2,500
mcg/mL
Draw Volume
0.040
mL
Syringe Units
4.0
units
Doses / Vial
50
doses

Summary: Add 2mL BAC water to your 5mg vial. Draw to 4.0 units on a U-100 syringe for a 100mcg dose. This vial will last 50 doses.

Cycle Planner

Subcutaneous or Intranasal. Typical beginner frequency: daily.

PE-22-28 Pharmacokinetics

Pharmacokinetics — Active Dose Over Time

t½ = ~23 hours (functional, animal data)
50%25%12.5%100%75%50%25%0%023h46h3d4d5dTime after injectionDose remaining
After 1 half-life (23h): 50% remainsAfter 2 half-lives (46h): 25% remainsAfter 3 half-lives (3d): 12.5% remains
At a 200mcg dose: 50% = 100mcg remaining after 23h. Recommended frequency: Daily.

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.

PE-22-28 Dosing Protocol

LevelDose / InjectionFrequency
Beginner100mcgDaily
Moderate200mcgDaily
Aggressive400mcgDaily

Note: Shortened spadin analog. TREK-1 potassium channel blocker (IC50 0.12 nM). Derived from sortilin propeptide. Animal research only — no human trials. Intranasal preferred for CNS access.

About PE-22-28

PE-22-28 is a synthetic heptapeptide (7 amino acids) derived from spadin, a naturally occurring fragment of the sortilin propeptide. It acts as a potent blocker of TREK-1 two-pore potassium channels in the brain, with an IC50 of 0.12 nM — roughly 300-fold more potent than the parent compound spadin. In animal models, PE-22-28 produces rapid antidepressant-like effects within 4 days of treatment, compared to the 3-4 weeks typical of SSRIs. It stimulates hippocampal neurogenesis, increases BDNF expression, and modulates serotonergic signaling. PE-22-28 also shows improved in vivo stability over spadin, with a functional duration of approximately 23 hours versus 7 hours. Preclinical stroke research has demonstrated neuroprotective effects, including reduced infarction size and improved motor and cognitive recovery. All current evidence comes from rodent studies — there are no published human clinical trials. This peptide remains strictly a research tool and should be approached with appropriate caution given the absence of human safety data.

Frequently Asked Questions